Antibody and diagnostic for dpp3, a biomarker of short

4TEEN4 Pharmaceuticals is focused on addressing the critical medical need associated with cardiogenic shock, a severe condition characterized by inadequate blood supply due to heart dysfunction, often following a myocardial injury. The company highlights the significant mortality rates associated with this condition, which can exceed 70% in intensive care settings. A key aspect of their approach is the identification of high-risk patients through the biomarker Dipeptidyl Peptidase 3 (DPP3), which is implicated in over 50% of cardiogenic shock cases. This biomarker allows for better stratification of patients, enabling targeted interventions.

To combat cardiogenic shock, 4TEEN4 Pharmaceuticals is developing Procizumab, a first-in-class therapeutic antibody designed to inhibit the DPP3 pathway. This innovative treatment aims to address the underlying pathophysiological mechanisms that contribute to the development of cardiogenic shock, potentially improving outcomes for patients who currently face high mortality rates despite existing treatment options. The company's commitment to advancing targeted therapies reflects a significant step forward in the management of this life-threatening condition.

Germany

Cardiogenic Shock: the primary circulatory shock in ICUs with a mortality rate over 70%. Triggered by acute myocardial injuries like heart attacks, it leads to severe left-ventricular dysfunction. Despite advancements in care and treatment for up to 200,000 affected U.S. patients annually, the first 30 days after diagnosis see persistently high mortality rates of 50-70%. Understand its pathophysiology, including the critical role of Dipeptidyl Peptidase 3, and the latest interventions.

4TEEN4 Pharmaceuticals

Company Details